• LAST PRICE
    0.7720
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.7700/ 1
  • Ask / Lots
    0.8400/ 4
  • Open / Previous Close
    0.0000 / 0.7720
  • Day Range
    ---
  • 52 Week Range
    Low 0.7452
    High 12.5500
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table
TimeVolumeSGTX
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesSGTX
Sigilon Therapeutics Inc
25.0M
-0.3x
---
United StatesTLIS
Talis Biomedical Corp
24.5M
-0.1x
---
United StatesAPVO
Aptevo Therapeutics Inc
23.8M
-0.8x
---
United StatesARAV
Aravive Inc
31.1M
-0.5x
---
United StatesCPHI
China Pharma Holdings Inc
12.1M
-3.2x
---
United StatesGTH
Genetron Holdings Ltd
124.1M
-1.7x
---
As of 2022-05-25

Company Information

Sigilon Therapeutics, Inc. is a biopharmaceutical company with a platform of biomedical technologies and cell therapies created to avoid host detection and foreign body responses with a goal of providing functional cures to patients with chronic diseases. The Company has developed its Shielded Living Therapeutics (SLTx) platform, which combines cell engineering in biocompatible materials and enables its product candidates to produce a range of therapeutic molecules, which may be missing or deficient, such as proteins, including therapeutic proteins and antibodies, and hormones. The Company is designing its product candidates to be off-the-shelf, durable, controllable and redosable, without requiring modification of the patient’s genes or immunosuppression. Its lead product candidate, SIG-001, is designed to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A by continuously secreting human Factor VIII (FVIII).

Contact Information

Headquarters
100 Binney Street, Ste 600CAMBRIDGE, MA, United States 02142
Phone
617-336-7540
Fax
302-655-5049

Executives

President, Chief Executive Officer, Director
Rogerio Vivaldi Coelho
Chief Financial Officer, Treasurer
Glenn Reicin
Executive Vice President, Chief Medical Officer
May Orfali
Chief Technical Operations Officer
Sarah Yuan
Independent Director
Douglas Cole

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$25.0M
Revenue (TTM)
$9.6M
Shares Outstanding
32.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-2.43
Book Value
$2.38
P/E Ratio
-0.3x
Price/Sales (TTM)
2.6
Price/Cash Flow (TTM)
---
Operating Margin
-787.97%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.